Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) CEO Ryan J. Watts sold 40,000 shares of the stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $27.69, for a total value of $1,107,600.00. Following the transaction, the chief executive officer now directly owns 235,807 shares of the company’s stock, valued at $6,529,495.83. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
Denali Therapeutics Trading Down 0.8 %
Shares of NASDAQ DNLI opened at $26.08 on Thursday. The firm has a market cap of $3.72 billion, a P/E ratio of -27.17 and a beta of 1.38. The business’s 50 day moving average is $26.98 and its 200-day moving average is $22.71. Denali Therapeutics Inc. has a 1-year low of $14.56 and a 1-year high of $32.13.
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.09. The firm had revenue of $1.00 million for the quarter, compared to the consensus estimate of $10.00 million. During the same quarter in the previous year, the business earned $1.30 EPS. The firm’s quarterly revenue was down 99.7% on a year-over-year basis. Analysts forecast that Denali Therapeutics Inc. will post -2.54 EPS for the current year.
Institutional Trading of Denali Therapeutics
Analysts Set New Price Targets
DNLI has been the topic of a number of analyst reports. Cantor Fitzgerald cut Denali Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday, October 7th. Wedbush cut their price target on shares of Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a research note on Friday, August 2nd. HC Wainwright restated a “buy” rating and set a $90.00 price objective on shares of Denali Therapeutics in a research note on Wednesday, September 4th. Bank of America raised their target price on shares of Denali Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Finally, JPMorgan Chase & Co. lowered their price target on Denali Therapeutics from $29.00 to $28.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $38.22.
Check Out Our Latest Analysis on DNLI
Denali Therapeutics Company Profile
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
Featured Articles
- Five stocks we like better than Denali Therapeutics
- What Are Trending Stocks? Trending Stocks Explained
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Trading Halts Explained
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.